🔥 FDA just *rejected* full approval for Adnexxa 🔥
likely due to increased thrombosis risk in ANEXA-I trial
IMHO the best strategy is to keep this off your hospital's formulary (thereby avoiding endless circular debates about Adnexxa vs PCC)
firstwordpharma.com/story/5921956 #EMIMCC
phenobarb all the way - quick onset, works well, and nearly nonexistent respiratory depression in my experience (even at very high cumulative doses). plus the long half life eliminates the need for a taper
Today's Paper of the Day is on management of CAR-T cell-associated toxicities
criticalcarereviews.com/latest-evide...
Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2024